Bacterial Control in Partial Thickness Burns Using Silver-containing Wound Dressings
Launched by UNIVERSITY HOSPITAL, GHENT · Jun 21, 2006
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Burn wounds with flux values, measured by Laser Doppler Imaging, corresponding with expected healing time between 7 and 21 days, flux values between 200 and 1000 (red-pink or pink-yellow-green colour)
- • Wounds treated with a hydrocolloid paste prior to LDI
- • Possibility to follow the complete treatment schedule until wound healing and participation on complete follow-up schedule
- • Informed consent
- • Partial thickness burns with TBSE \< 40%
- Exclusion Criteria:
- • Mean flux values \< 200 or \> 1000
- • TBSA \> 40%
- • Impossibility to debride necrotic skin prior to LDI measurement
- • Wounds treated with any topical ointments or dressings other than hydrocolloid prior to LDI
- • Not following the complete treatment schedule or missing some evaluations during the follow-up period
- • Patient has any condition that seriously compromises the patient's ability to complete the study
- • Patient has participated in another study using an investigational drug within the previous 30 days
- • Patient has one or more medical condition(s)that in the opinion of the investigator would make the patient an inappropriate candidate for this study
- • The plastic surgeon decides that surgery is necessary due to unusual circumstances
- • Patient wish to decline from the study
- • No informed consent
- • Full thickness burns
About University Hospital, Ghent
University Hospital Ghent is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. Located in Ghent, Belgium, the hospital is affiliated with Ghent University, fostering a collaborative environment that integrates cutting-edge medical research with high-quality patient care. With a diverse range of specialized departments and a dedicated team of researchers and clinicians, University Hospital Ghent is at the forefront of developing new therapies and improving treatment protocols, aiming to enhance patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ghent, , Belgium
Patients applied
Trial Officials
Stan Monstrey, MD, PhD
Principal Investigator
University Hospital, Ghent
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials